Melanoma Clinical Trials in New York

Showing 41-60 of 311 trials

A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

NCT05912244

The researchers are doing this study to find out whether the study vaccines, IO102/IO103, given in combination with the standard-of-care drug combination, nivolumab and relatlimab, is a safe and effective treatment for people with untreated, unresectable melanoma.

Melanoma

Memorial Sloan Kettering Cancer Center43 participantsStarted Jun 2023

Hartford, Connecticut, United States • Basking Ridge, New Jersey, United States • Middletown, New Jersey, United States +6 more locations

Active Not RecruitingPhase 1< 1 mile

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

NCT04044859

This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, esophageal, esophagogastric junction (EGJ), gastric, head and neck, melanoma, non-small cell lung (NSCLC), ovarian or urothelial cancer.

Endometrial CancerEsophageal CancerEsophagogastric Junction (EGJ)+6 more

USWM CT, LLC120 participantsStarted Aug 2019

Orlando, Florida, United States • Boston, Massachusetts, United States • St Louis, Missouri, United States +14 more locations

A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

Melanoma Trials in Other Cities

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

Treating Patients With Melanoma and ALK Alterations With Ensartinib

Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Patient Satisfaction With Appearance, Scar Outcome and Quality of Life After Skin Cancer Surgery

Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery

A Study of MGC026 in Participants With Advanced Solid Tumors

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

Other Conditions in New York